Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry and Preliminary Activity of [177Lu]Lu-FF58 in Patients With Selected Advanced Solid Tumors.

Next Previous
Trial Profile

A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry and Preliminary Activity of [177Lu]Lu-FF58 in Patients With Selected Advanced Solid Tumors.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 31 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 177Lu-FF58 (Primary) ; 68Ga-FF58 (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Glioblastoma; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 27 Dec 2024 Status changed from active, no longer recruiting to discontinued.
  • 28 Nov 2024 Planned End Date changed from 26 Jan 2027 to 16 Dec 2024.
  • 28 Nov 2024 Planned primary completion date changed from 26 Jan 2027 to 16 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top